换一批
换一批Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
作者：
主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);苯甲酰胺类(Benzamides);卡方分布(Chi-Square Distribution);无病生存(Disease-Free Survival);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);德国(Germany);人类(Humans);干扰素α(Interferon-alpha);Kaplan-Meiers评估(Kaplan-Meier Estimate);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);男(雄)性(Male);中年人(Middle Aged);哌嗪类(Piperazines);蛋白激酶抑制剂(Protein Kinase Inhibitors);嘧啶类(Pyrimidines);缓解诱导(Remission Induction);危险性评估(Risk Assessment);危险因素(Risk Factors);存活率(Survival Rate);时间因素(Time Factors);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.1200/JCO.2010.32.0598
PMID
21422420
发布时间
2022-03-21
- 浏览23
Journal of clinical oncology
1634-42页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
